)
Gian Luca Araldi, PhD, PharmD
CEO
Avanti Biosciences, Inc.
Dr. Araldi brings over 30 years of drug development experience, having successfully advanced multiple compounds from discovery through clinical development. As CEO of Avanti Biosciences, he has secured ~$7M in NIH funding and achieved FDA Orphan Drug Designation for ABI-171, a novel anti-fibrotic compound. Previously served in academic leadership roles and has extensive experience in translational medicine, particularly in fibrotic disease research. Dr. Araldi has published extensively on kinase inhibitor development and has presented at major industry conferences, including previous BIO conventions.
Sessions
-
22-Jun-2026Theater 4Avanti Biosciences, Inc.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}